# Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT05613894** · PHASE1 · RECRUITING · sponsor: **University of Utah** · enrollment: 33 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT05613894
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2026-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05613894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05613894, "Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05613894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*